News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
WINLEVI works differently from any other topical acne treatment
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Plans to double its manufacturing footprint to bolster the growth
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
_256_384.jpg){kind=logo}
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
Subscribe To Our Newsletter & Stay Updated
